Thymidylate synthase: a critical target in cancer therapy?

Frontiers in Bioscience : a Journal and Virtual Library
Youcef M Rustum

Abstract

For the last four decades, synthesis and testing of potentially active drugs (e.g., antimetabolites) have focused on structural modification of existing metabolites as precursors of DNA and RNA synthesis. In recent years, the focus has shifted to synthesis of target-specific agents. Thus, the current emphasis of drug development is directed at inhibiting specific target(s) expressed preferentially, if not exclusively, in tumor tissues, with the ultimate goal of improving the therapeutic efficacy and selectivity of these new agents. Preclinically, proof-of-principle studies were carried out in tumors with specific expression of the intended target. With the hope of translating preclinical findings to the design of implementation of clinical trials. Thymidylate synthase (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis. While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex) and AG337 (Thymitag) are more specific and potent TS inhibitors. Thus, it is hoped that pronounced ...Continue Reading

Citations

Sep 15, 2005·Journal of Cancer Research and Clinical Oncology·Marina PavlakMarko Radacić
Nov 26, 2010·Molecular Biology Reports·Maria Wisniewska-JarosinskaAlina Morawiec-Sztandera
Jan 14, 2010·Annals of Nuclear Medicine·Ioannis Trigonis, Alan Jackson
Oct 17, 2007·Journal of Biomolecular Structure & Dynamics·Abul HasnatJulie Andrews
Jul 12, 2014·BioMed Research International·Mohamed HassanNoriaki Sakuragi
Apr 29, 2010·Journal of Cancer Research and Clinical Oncology·Dimitrios J StravopodisGerassimos E Voutsinas
Dec 7, 2010·Pharmacotherapy·Sachin R ShahSarah M Gressett Ussery
Nov 23, 2006·Toxicology in Vitro : an International Journal Published in Association with BIBRA·S GiudiceC Magnoni
Jan 7, 2011·Journal of Oncology·Muhammad Wasif SaifKostas Syrigos
Jun 3, 2015·Cancer Immunology, Immunotherapy : CII·Maria Grazia CusiPierpaolo Correale
Sep 11, 2007·Archives of Biochemistry and Biophysics·Per LindblomBjörn Glinghammar
Jun 27, 2019·International Journal of Surgical Pathology·Rui GuoJun Yang
Mar 7, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bin LiAnnie L M Cheung
Aug 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marie-Christine Etienne-GrimaldiGérard Milano
Jun 24, 2009·Chemical Reviews·Mats Ljungman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Related Papers

Proceedings of the National Academy of Sciences of the United States of America
E ChuC J Allegra
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
S P StrattonD S Alberts
Journal of the National Cancer Institute
P SkehanM R Boyd
© 2021 Meta ULC. All rights reserved